|
Synonyms: TJ 003234 | TJ003234 | TJM2
Compound class:
Antibody
Comment: Plonmarlimab (TJM2/TJ003234) is a humanized IgG1 monoclonal antibody that is designed to neutralise granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) cytokine activity. It was developed by I-Mab Biopharma for potential to treat autoimmune diseases, and is likely to be Hu23F4-27 as claimed in I-Mab patent WO2018050111A1 [2].
COVID-19: Plonmarlimab is being evaluated as a mechanism to down-regulate elevated inflammation/cytokine release syndrome in patients with COVID-19 [1] in a Phase 2/3 study. |
| No information available. |
Summary of Clinical Use  |
| Plonmarlimab (TJM2/TJ003234) has advanced to clinical evaluations to determine safety and anti-inflammatory efficacy, principally for autoimmune diseases. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03794180 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects | Phase 1 Interventional | I-Mab Biopharma Co. Ltd. | ||
| NCT04341116 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | Phase 2/Phase 3 Interventional | I-Mab Biopharma Co. Ltd. | ||
| NCT04457856 | A Study of TJ003234 in Rheumatoid Arthritis Patients | Phase 1 Interventional | I-Mab Biopharma Co. Ltd. | Patient dosing in this study began in August 2020. | |
